

XNK Therapeutics to present at ABGSC Private Companies Seminar on December 6

December 01, 2021

XNK Therapeutics AB's CEO, Johan Liwing, will present at the ABGSC Private Companies event on December 6. The presentation starts at 09:30CET and will be livestreamed via <https://www.introduce.se>.

The presentation will be held in English and will also be available on XNK's website www.xnktherapeutics.com shortly thereafter.

For more information, please contact:

Johan Liwing, CEO, XNK Therapeutics

Tel: +46 706 70 36 75

E-mail: johan.liwing@xnktherapeutics.com

About XNK Therapeutics AB

XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and lead investigational candidate drug was developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Company's objective is for its investigational candidate drug and proprietary platform technology to constitute key components in the cancer treatments of tomorrow. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.